Gene expression profiling of KBH-A42, a novel histone deacetylase inhibitor, in human leukemia and bladder cancer cell lines

Saito A, Yamashita T, Mariko Y, et al: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA. 96:4592–4597. 1999. View Article : Google Scholar : PubMed/NCBI

Saunders NA, Popa C, Serewko MM, Jones SJ, Dicker AJ and Dahler AL: Histone deacetylase inhibitors: novel anticancer agents. Expert Opin Investig Drugs. 8:1611–1621. 1999. View Article : Google Scholar : PubMed/NCBI

Grunstein M: Histone acetylation in chromatin structure and transcription. Nature. 389:349–352. 1997. View Article : Google Scholar : PubMed/NCBI

Chambers AE, Banerjee S, Chaplin T, et al: Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer. 39:1165–1175. 2003. View Article : Google Scholar : PubMed/NCBI

Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG and Davidsen SK: Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther. 2:151–163. 2003.PubMed/NCBI

Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA. 101:540–545. 2004. View Article : Google Scholar : PubMed/NCBI

Peart MJ, Smyth GK, van Laar RK, et al: Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA. 102:3697–3702. 2005. View Article : Google Scholar

Sasakawa Y, Naoe Y, Sogo N, et al: Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol. 69:603–616. 2005. View Article : Google Scholar : PubMed/NCBI

Gray SG, Qian CN, Furge K, Guo X and Teh BT: Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol. 24:773–795. 2004.PubMed/NCBI

Butler LM, Agus DB, Scher HI, et al: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60:5165–5170. 2000.PubMed/NCBI

Richon VM, Sandhoff TW, Rifkind RA and Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 97:10014–10019. 2000. View Article : Google Scholar : PubMed/NCBI

Kang MR, Kang JS, Han SB, et al: A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells. Biochem Pharmacol. 78:486–494. 2009. View Article : Google Scholar : PubMed/NCBI

Kang MR, Lee K, Kang JS, et al: KBH-A42, a histone deacetylase inhibitor, inhibits the growth of doxorubicin-resistant leukemia cells expressing P-glycoprotein. Oncol Rep. 23:801–809. 2010.PubMed/NCBI

Lee SD, Park SK, Lee ES, et al: A lipid-soluble red ginseng extract inhibits the growth of human lung tumor xenografts in nude mice. J Med Food. 13:1–5. 2010. View Article : Google Scholar : PubMed/NCBI

Louis M, Rosato RR, Brault L, et al: The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress. Int J Oncol. 25:1701–1711. 2004.

Doi S, Soda H, Oka M, et al: The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol Cancer Ther. 3:1397–1402. 2004.PubMed/NCBI

Roh MS, Kim CW, Park BS, et al: Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells. Apoptosis. 9:583–589. 2004. View Article : Google Scholar : PubMed/NCBI

Willis SN and Adams JM: Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol. 17:617–625. 2005. View Article : Google Scholar : PubMed/NCBI

Inohara N, Ding L, Chen S and Nunez G: Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J. 16:1686–1694. 1997. View Article : Google Scholar : PubMed/NCBI

Takimoto R and El-Deiry WS: Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene. 19:1735–1743. 2000. View Article : Google Scholar : PubMed/NCBI

Stehlik C, Lee SH, Dorfleutner A, Stassinopoulos A, Sagara J and Reed JC: Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J Immunol. 171:6154–6163. 2003. View Article : Google Scholar : PubMed/NCBI

Staber PB, Noehammer C, Durkop H, et al: mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin’s lymphoma. Leuk Res. 30:343–348. 2006.PubMed/NCBI